These data suggest that in addition to the early anti-inflammatory role that B-lymphocytes play in the acute phase of stroke, there is a second B-lymphocyte response to unidentified antigens during the chronic phase that features the maturation of activated B-lymphocytes into IgA + PCs. This evidence concerns the gene CD79A and stroke disorder.